阿帕他胺与非转移性去势抵抗性前列腺癌总生存:SPARTAN研究第二次中期分析
第二次预设中期分析中位随访41个月,阿帕他胺较安慰剂改善总生存(HR 0.75;95%CI 0.59-0.96;P=0.0197),但P值未跨预设O'Brien-Fleming边界0.0121;PFS2亦改善(HR 0.55;95%CI 0.45-0.68),未观察到新安全性信号。
要点
- 阿帕他胺降低nmCRPC患者死亡风险25%(HR 0.75;95%CI 0.59-0.96)
- OS获益在安慰剂组交叉及后续延长生存治疗比例更高情况下仍观察到
- PFS2显著改善(HR 0.55;95%CI 0.45-0.68),无新安全性信号
核心结论
- 在nmCRPC患者中,阿帕他胺较安慰剂降低25%死亡风险,尽管安慰剂组交叉及后续延长生存治疗比例更高。
研究设计与样本
- 第二次预设中期分析(IA2)时中位随访41个月,采用O'Brien-Fleming型α消耗函数进行组序贯OS检验。
主要发现
- IA2时OS事件数为285例(为计划最终分析所需事件的67%),阿帕他胺组OS较安慰剂组改善(HR 0.75;95%CI 0.59-0.96;P=0.0197),但P值未跨预设O'Brien-Fleming边界0.0121。
- 阿帕他胺改善至第二次进展的无进展生存(PFS2)(HR 0.55;95%CI 0.45-0.68)。
- IA2时安慰剂组69%、阿帕他胺组40%的患者接受了针对转移性CRPC的后续延长生存治疗。
- 未观察到新的安全性信号。
临床怎么用
- 对于高危nmCRPC患者,在持续雄激素剥夺治疗基础上加用阿帕他胺可改善总生存,且安全性可控。
局限性
- OS结果为第二次预设中期分析,P值未跨预设O'Brien-Fleming边界0.0121,尚需最终分析确认。
- 安慰剂组患者交叉接受开放标签阿帕他胺及后续延长生存治疗比例更高,可能影响OS的组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS) and time to symptomatic progression in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Overall survival (OS) results at the first interim analysis (IA1) were immature, with 104 of 427 (24%) events required for planned final OS analysis. Here, we report the results of a second pre-specified interim analysis (IA2). METHODS: One thousand two hundred and seven patients with nmCRPC were randomized 2 : 1 to apalutamide (240 mg daily) or placebo. The primary end point of the study was MFS. Subsequent therapy for metastatic CRPC was permitted. When the primary end point was met, the study was unblinded. Patients receiving placebo who had not yet developed metastases were offered open-label apalutamide. At IA2, pre-specified analysis of OS was undertaken, using a group-sequential testing procedure with O'Brien-Fleming-type alpha spending function. Safety and second progression-free survival (PFS2) were assessed. RESULTS: Median follow-up was 41 months. With 285 (67% of required) OS events, apalutamide was associated with an improved OS compared with placebo (HR 0.75; 95% CI 0.59-0.96; P = 0.0197), although the P-value did not cross the pre-specified O'Brien-Fleming boundary of 0.0121. Apalutamide improved PFS2 (HR 0.55; 95% CI 0.45-0.68). At IA2, 69% of placebo-treated and 40% of apalutamide-treated patients had received subsequent life-prolonging therapy for metastatic CRPC. No new safety signals were observed. CONCLUSION: In patients with nmCRPC, apalutamide was associated with a 25% reduction in risk of death compared with placebo. This OS benefit was observed despite crossover of placebo-treated patients and higher rates of subsequent life-prolonging therapy for the placebo group.
引用
- Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019. PMID: 31560066. doi:10.1093/annonc/mdz397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。